Notification of date for FY23 results release
Released
Released
Announcement PDF
ASX Announcement
FY23 RESULTS RELEASE AND INVESTOR CALL
23 August 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX:MYX) announces that it
will release its financial statements for the year ended 30 June 2023 on Thursday 31 August 2023.
Mayne Pharma’s CEO Mr Shawn Patrick O’Brien and CFO Mr Aaron Gray will host a webcast of the
results at 9.30am AEST on Thursday 31 August 2023. Participants can register for the webcast by
navigating to https://s1.c-conf.com/diamondpass/10031692-uts5ef.html.
For further information contact:
Australia:
Craig Haskins
+61 421 029 843
ir@maynepharma.com
US:
Lisa M. Wilson
+917 543 9932
ir@maynepharma.com
Authorised for release to the ASX by the Chair
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel
pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also
provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40year track record of innovation and success in developing new oral drug delivery systems. These
technologies have been successfully commercialised in numerous products that continue to be marketed
around the world. To learn more about Mayne Pharma, please visit maynepharma.com.
Share your feedback
Discover